Clinical Trials

What this episode covers

The extraordinary success of the creation of vaccines for Covid-19 has made the business of clinical trials look simple. But appearances can be deceptive and it usually takes many years and costs hundreds of millions of pounds to bring a new drug, therapy or medical device successfully to market.Evan Davis and his guests discuss how the economics of commercial clinical trials now look for companies in the light of such a disruptive event as the pandemic. How far is greater collaboration - with start-ups partnering with big pharma and research companies - changing the way in which trials operate? And will new tech developments - like the greater, tailored use of Artificial Intelligence, digital data and advanced statistical techniques - make the process cheaper and quicker - while compromising neither safety nor patient confidentiality?Those taking part are: Nuala Murphy of the executive team at Icon plc, a Dublin-based clinical research organisation which last year worked with Pfizer/BioNTech on their Covid-19 vaccine; Houman Ashrafian, managing partner of the biotech team at SVHealth Investors, a venture capital firm with offices in London and Boston; and Avideh Nazeri, vice-president in the UK for clinical development, medical and regulatory affairs at the Danish-headquartered integrated pharmaceutical company, Novo Nordisk.Editor Hugh Levinson

PodParley-generated summary based on available episode metadata and transcript content.